ATE388707T1 - Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen - Google Patents
Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungenInfo
- Publication number
- ATE388707T1 ATE388707T1 AT00932162T AT00932162T ATE388707T1 AT E388707 T1 ATE388707 T1 AT E388707T1 AT 00932162 T AT00932162 T AT 00932162T AT 00932162 T AT00932162 T AT 00932162T AT E388707 T1 ATE388707 T1 AT E388707T1
- Authority
- AT
- Austria
- Prior art keywords
- tramadol
- bimodally
- analgesic
- opioid agonist
- acting opioid
- Prior art date
Links
- 230000000202 analgesic effect Effects 0.000 title abstract 4
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 229960004380 tramadol Drugs 0.000 title abstract 3
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title abstract 3
- 239000003401 opiate antagonist Substances 0.000 title abstract 2
- 239000003402 opiate agonist Substances 0.000 abstract 5
- 206010001497 Agitation Diseases 0.000 abstract 2
- 208000004454 Hyperalgesia Diseases 0.000 abstract 2
- 208000035154 Hyperesthesia Diseases 0.000 abstract 2
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 abstract 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002964 excitative effect Effects 0.000 abstract 1
- 229960005297 nalmefene Drugs 0.000 abstract 1
- 229960003086 naltrexone Drugs 0.000 abstract 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/306,164 US20010006967A1 (en) | 1992-09-21 | 1999-05-06 | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE388707T1 true ATE388707T1 (de) | 2008-03-15 |
Family
ID=23184116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00932162T ATE388707T1 (de) | 1999-05-06 | 2000-05-05 | Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20010006967A1 (de) |
| EP (1) | EP1178803B1 (de) |
| JP (1) | JP2002544160A (de) |
| AT (1) | ATE388707T1 (de) |
| AU (1) | AU782533B2 (de) |
| CA (1) | CA2373348A1 (de) |
| DE (1) | DE60038290D1 (de) |
| WO (1) | WO2000067739A2 (de) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| DK1685839T3 (da) | 1997-12-22 | 2013-06-24 | Euro Celtique Sa | Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist |
| AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| ITMI20010907A1 (it) * | 2001-05-02 | 2002-11-02 | Valpharma Sa | Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi |
| CN1592609A (zh) * | 2001-05-11 | 2005-03-09 | 恩德制药公司 | 抗滥用阿片样物质剂型 |
| CN1525851A (zh) | 2001-05-11 | 2004-09-01 | ������ҩ������˾ | 抗滥用阿片样物质控释剂型 |
| US7943173B2 (en) | 2001-07-18 | 2011-05-17 | Purdue Pharma L.P. | Pharmaceutical combinations of oxycodone and naloxone |
| US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| US20060177381A1 (en) * | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
| CA2478515C (en) | 2002-04-05 | 2010-09-28 | Purdue Pharma | Pharmaceutical preparation containing oxycodone and naloxone |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
| US9539221B2 (en) * | 2003-10-09 | 2017-01-10 | Egb Advisors, Llc | Method of treating airway diseases with β-adrenergic inverse agonists |
| US20070276024A1 (en) * | 2003-10-09 | 2007-11-29 | Inverseon , Inc. | Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists |
| EP1604666A1 (de) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit |
| US20060052856A1 (en) | 2004-09-08 | 2006-03-09 | Kim Daniel H | Stimulation components |
| US20120277839A1 (en) | 2004-09-08 | 2012-11-01 | Kramer Jeffery M | Selective stimulation to modulate the sympathetic nervous system |
| US9205261B2 (en) | 2004-09-08 | 2015-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Neurostimulation methods and systems |
| US7528175B2 (en) * | 2004-10-08 | 2009-05-05 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
| EP1702558A1 (de) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
| WO2007120864A2 (en) * | 2006-04-14 | 2007-10-25 | Shire Llc | Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse |
| EP1897543A1 (de) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine-Waffel zur Substitutionstherapie |
| US9314618B2 (en) | 2006-12-06 | 2016-04-19 | Spinal Modulation, Inc. | Implantable flexible circuit leads and methods of use |
| WO2008070808A2 (en) | 2006-12-06 | 2008-06-12 | Spinal Modulation, Inc. | Expandable stimulation leads and methods of use |
| CA2671286C (en) | 2006-12-06 | 2017-09-19 | Spinal Modulation, Inc. | Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels |
| CA2676804A1 (en) | 2007-01-29 | 2008-08-07 | Spinal Modulation, Inc. | Sutureless lead retention features |
| NZ579169A (en) * | 2007-02-12 | 2012-05-25 | Dmi Biosciences Inc | Treatment of comorbid premature ejaculation and erectile dysfunction using tramadol and a phosphodiesterase (pde) inhibitor |
| DK2114147T3 (da) | 2007-02-12 | 2012-06-25 | Dmi Biosciences Inc | Reduktion af bivirkninger af tramadol |
| WO2009106831A2 (en) | 2008-02-28 | 2009-09-03 | Syntropharma Limited | Pharmaceutical composition |
| EP2373378B1 (de) | 2008-10-27 | 2017-04-26 | Spinal Modulation Inc. | Selektive stimulationssysteme und signalparameter für medizinische erkrankungen |
| WO2010103039A1 (en) | 2009-03-10 | 2010-09-16 | Euro-Celtique S.A. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
| AU2010229985B2 (en) | 2009-03-24 | 2015-09-17 | Spinal Modulation, Inc. | Pain management with stimulation subthreshold to paresthesia |
| CA2761778A1 (en) | 2009-05-15 | 2010-11-18 | Spinal Modulation, Inc. | Methods, systems and devices for neuromodulating spinal anatomy |
| US8202525B2 (en) | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| AU2011250941A1 (en) | 2010-05-10 | 2012-11-29 | Spinal Modulation, Inc. | Methods, systems and devices for reducing migration |
| CA2825763A1 (en) | 2011-02-02 | 2012-08-09 | Spinal Modulation, Inc. | Devices, systems and methods for the targeted treatment of movement disorders |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| KR20180037074A (ko) | 2013-07-23 | 2018-04-10 | 유로-셀티큐 에스.에이. | 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물 |
| IL318587A (en) | 2018-07-23 | 2025-03-01 | Trevi Therapeutics Inc | Treatment of chronic cough, shortness of breath and wheezing |
| CA3166928A1 (en) | 2020-01-10 | 2021-07-15 | Trevi Therapeutics, Inc. | Methods of administering nalbuphine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2728240B2 (ja) * | 1988-07-26 | 1998-03-18 | ヘキスト薬品工業株式会社 | ヒトプロテインｃ変異体及びその製造方法 |
-
1999
- 1999-05-06 US US09/306,164 patent/US20010006967A1/en not_active Abandoned
-
2000
- 2000-05-05 JP JP2000616766A patent/JP2002544160A/ja not_active Withdrawn
- 2000-05-05 WO PCT/US2000/012493 patent/WO2000067739A2/en not_active Ceased
- 2000-05-05 CA CA002373348A patent/CA2373348A1/en not_active Abandoned
- 2000-05-05 AT AT00932162T patent/ATE388707T1/de not_active IP Right Cessation
- 2000-05-05 EP EP00932162A patent/EP1178803B1/de not_active Expired - Lifetime
- 2000-05-05 AU AU49928/00A patent/AU782533B2/en not_active Ceased
- 2000-05-05 DE DE60038290T patent/DE60038290D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1178803B1 (de) | 2008-03-12 |
| WO2000067739A3 (en) | 2001-01-25 |
| US20010006967A1 (en) | 2001-07-05 |
| CA2373348A1 (en) | 2000-11-16 |
| EP1178803A2 (de) | 2002-02-13 |
| DE60038290D1 (de) | 2008-04-24 |
| JP2002544160A (ja) | 2002-12-24 |
| AU4992800A (en) | 2000-11-21 |
| AU782533B2 (en) | 2005-08-04 |
| WO2000067739A2 (en) | 2000-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60038290D1 (de) | Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen | |
| EP1539234A4 (de) | Verfahren zur prävention oder behandlung von zellmalignität durch verabreichung von cd2-antagonisten | |
| ATE446751T1 (de) | Verwendung von methylnaltrexon zur behandlung von immunsuppression | |
| YU42402A (sh) | Jedinjenja karbamida koja imaju antagonističku aktivnost na muskarinski receptor | |
| DK1135153T3 (da) | Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser | |
| WO2001037785A3 (en) | Novel methods and compositions involving opioids and antagonists thereof | |
| MXPA04008772A (es) | Composiciones de clorhidrato de naltrexona. | |
| ATE414515T1 (de) | Medikamente zur gleichzeitigen erhöhung der analgetischen wirksamkeit und verminderung des abhängigkeitspotentials, die durch exogene und endogene opioidagonisten verursacht werden | |
| MXPA05010819A (es) | Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable. | |
| WO2005041891A3 (en) | Neutrophil activation by immune response modifier compounds | |
| NO20035025L (no) | Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. | |
| WO2003037271A3 (en) | Compounds, pharmaceutical compositions and methods of use therefor | |
| ATE419848T1 (de) | Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1 | |
| MXPA05003501A (es) | Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen. | |
| IL162616A0 (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
| SI1735278T1 (sl) | Agenti histamin h receptorja priprava in terapevtska uporaba | |
| WO2001001972A3 (en) | SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | |
| WO2002043807A3 (en) | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction | |
| EA200400734A1 (ru) | Способ и композиция для потенциирования действия опиатного анальгетика | |
| EA200001112A1 (ru) | Безводные и моногидратные формы n- (3-этинилфениламино)-6,7- бис (2-метоксиэтокси)-4-хиназолинамина мезилата | |
| MXPA03009595A (es) | Uso de antagonistas del canal de sodio neuronal para control de ectoparasitos de animales homeotermicos. | |
| WO2001085150A3 (en) | Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists | |
| EP1262196A3 (de) | Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht | |
| EE200100520A (et) | N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena | |
| WO2007056142A3 (en) | Methods of preventing the serotonin syndrome and compositions for use therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |